Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Executive Summary
Amgen Inc. appears to have a smooth path to FDA approval of its biosimilar of AbbVie Inc.'s tumor necrosis factor Humira (adalimumab) based on documents released ahead of a July 12 advisory committee meeting. But don't expect AbbVie to just sit back and take it.
You may also be interested in...
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
With continued strong growth for Humira, AbbVie doubles down on confidence to protect the franchise with IP strategy. Imbruvica and Viekira Pak show growth, although the latter is flourishing only ex-US.